[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline]

Arch Bronconeumol. 2009 Feb;45(2):100-2. doi: 10.1016/j.arbres.2008.01.003.
[Article in Spanish]


Cabergoline is a synthetic dopamine agonist used to treat Parkinson disease. The drug occasionally induces pleuropulmonary adverse effects, which manifest as pleural thickening or effusion, interstitial pneumonitis, pulmonary infiltrates, or fibrosis. We report a rare case of pleural effusion and severe pulmonary hypertension in a 79-year-old man with Parkinson disease who had been treated with cabergoline for 1 year. The symptoms disappeared 10 months after the drug was discontinued.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiparkinson Agents / adverse effects*
  • Cabergoline
  • Ergolines / adverse effects*
  • Humans
  • Hypertension, Pulmonary / chemically induced*
  • Male
  • Parkinson Disease / drug therapy*
  • Pleural Effusion / chemically induced*


  • Antiparkinson Agents
  • Ergolines
  • Cabergoline